BerGenBio ASA (FRA:7BG0)
€ 0.708 0.009 (1.29%) Market Cap: 28.14 Mil Enterprise Value: 13.42 Mil PE Ratio: 0 PB Ratio: 2.14 GF Score: 58/100

Q4 2022 Bergenbio ASA Earnings Call Transcript

Feb 16, 2023 / 09:00AM GMT
Release Date Price: €35.01 (+2.28%)
Martin Olin
BerGenBio ASA - CEO

Good morning and welcome to BerGenBio's fourth-quarter financial report and business update. I'm Martin Olin, the CEO of BerGenBio. Today, I will, together with Cristina Oliva, our Chief Medical Officer, take you through a business update centered around our strategic focus in lung cancer and severe respiratory infections.

Just remind everyone about the formalities. So yesterday, BerGenBio announced the topline data from our second line non-small cell lung cancer study in which we have enrolled patients who have received at least one prior line of therapy, and the patients were treated in a combination of bemcentinib, our selective AXL inhibitor, in combination with pembrolizumab. And it's with great confidence that I can say that it actually does matter to inhibit AXL, specifically in non-small cell lung cancer.

The topline data we announced yesterday, very clearly show that AXL inhibition makes a difference. And we saw that in terms of very significant clinical benefit for the patients who received the combination of bemcentinib in combination with

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot